Literature DB >> 11169244

Functional topography of discrete domains of human CD38.

C M Ausiello1, F Urbani, R Lande, A la Sala, B Di Carlo, G Baj, N Surico, J Hilgers, S Deaglio, A Funaro, F Malavasi.   

Abstract

In addition to its catalytic activities as ecto-NAD+ glycohydrolase (NADase), CD38 displays the ability to transduce signals of biological relevance. Indeed, ligation of CD38 on peripheral blood mononuclear cells (PBMC) by agonistic monoclonal antibodies (mAbs) is followed by the transcription and secretion of a vast array of regulatory cytokines. The present work addresses the issue of whether the signals leading to calcium (Ca2+) mobilization, lymphocyte proliferation and release of cytokines is dependent on the epitopes recognized by the individual mAbs. Competition binding analysis identifies two families of mAbs, namely IB4, IB6 and AT2 on one side and OKT10, SUN-4B7 and AT1 on the other. Each mAb family binds epitopes that are completely or partially common. However, the functional activities of the CD38 molecule can not be simply attributed to the epitopes engaged: for instance, IB4 and OKT10 mAbs, which bind different epitopes, perform as agonistic mAbs in inducing PBMC proliferation and interferon (IFN)-gamma secretion. SUN-4B7 yields intermediate effects, whereas IB6, AT1 and AT2 mAbs are totally ineffective. The effects mediated by IB4 and OKT10 mAbs are apparent in 80% of the healthy individuals studied, whereas the effects of SUN-4B7 mAb operate only in 25% of the donors. Interleukin (IL)-6 secretion was observed in all individuals analyzed, irrespective of the epitopes triggered and of mAbs used to ligate the CD38 molecule. In addition, IB4 is the only mAb able to induce significant intracellular Ca2+ fluxes.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11169244     DOI: 10.1034/j.1399-0039.2000.560608.x

Source DB:  PubMed          Journal:  Tissue Antigens        ISSN: 0001-2815


  7 in total

1.  CD38 and CD157 ectoenzymes mark cell subsets in the human corneal limbus.

Authors:  Alberto L Horenstein; Federico Sizzano; Riccardo Lusso; Federico Genzano Besso; Enza Ferrero; Silvia Deaglio; Franco Corno; Fabio Malavasi
Journal:  Mol Med       Date:  2008-11-19       Impact factor: 6.354

2.  Conformational Closure of the Catalytic Site of Human CD38 Induced by Calcium.

Authors:  Qun Liu; Richard Graeff; Irina A Kriksunov; Connie M C Lam; Hon Cheung Lee; Quan Hao
Journal:  Biochemistry       Date:  2008-12-30       Impact factor: 3.162

3.  Mechanism-based small molecule probes for labeling CD38 on live cells.

Authors:  Hong Jiang; Johanna Congleton; Qun Liu; Paolomi Merchant; Fabio Malavasi; Hon Cheung Lee; Quan Hao; Andrew Yen; Hening Lin
Journal:  J Am Chem Soc       Date:  2009-02-11       Impact factor: 15.419

4.  A CD38/CD203a/CD73 ectoenzymatic pathway independent of CD39 drives a novel adenosinergic loop in human T lymphocytes.

Authors:  Alberto L Horenstein; Antonella Chillemi; Gianluca Zaccarello; Santina Bruzzone; Valeria Quarona; Andrea Zito; Sara Serra; Fabio Malavasi
Journal:  Oncoimmunology       Date:  2013-09-26       Impact factor: 8.110

5.  CD38 ligation in peripheral blood mononuclear cells of myeloma patients induces release of protumorigenic IL-6 and impaired secretion of IFNγ cytokines and proliferation.

Authors:  Giorgio Fedele; Marco Di Girolamo; Umberto Recine; Raffaella Palazzo; Francesca Urbani; Alberto L Horenstein; Fabio Malavasi; Clara Maria Ausiello
Journal:  Mediators Inflamm       Date:  2013-12-30       Impact factor: 4.711

6.  Probing the requirement for CD38 in retinoic acid-induced HL-60 cell differentiation with a small molecule dimerizer and genetic knockout.

Authors:  Robert J MacDonald; Jonathan H Shrimp; Hong Jiang; Lu Zhang; Hening Lin; Andrew Yen
Journal:  Sci Rep       Date:  2017-12-12       Impact factor: 4.379

7.  Characterization and phylogenetic epitope mapping of CD38 ADPR cyclase in the cynomolgus macaque.

Authors:  Enza Ferrero; Monia Orciani; Paola Vacca; Erika Ortolan; Sergio Crovella; Fausto Titti; Franca Saccucci; Fabio Malavasi
Journal:  BMC Immunol       Date:  2004-09-21       Impact factor: 3.615

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.